Latest Heart failure Stories

FRAMINGHAM, Mass. and SYDNEY, Feb. 28, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Raymond James 34(th) Annual Institutional Investors Conference at 1:05 p.m. Eastern Standard Time on Tuesday, March 5, 2013. The conference is being...

Together, SynCardia's 70cc and 50cc Total Artificial Hearts Will Fit Almost All Adult Men and Women, and Many Adolescents TUCSON, Ariz., Feb. 28, 2013 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that the U.S. Food and Drug Administration (FDA) has approved two Humanitarian Use Device (HUD) designations for the new 50cc Total Artificial Heart...

New technology can save lives for those suffering from end-stage bi-ventricular heart failure NEW ORLEANS, Feb. 27, 2013 /PRNewswire/ -- The John Ochsner Heart & Vascular Institute (JOHVI) at Ochsner Medical Center has performed the Gulf South Region's first Total Artificial Heart (TAH) implant. The latest advancement in mechanical heart technology, the SynCardia TAH is the world's first and only FDA approved device. (Logo:...

Among patients with heart failure with preserved ejection fraction, long-term treatment with the medication spironolactone improved left ventricular diastolic function but did not affect maximal exercise capacity, patient symptoms, or quality of life, according to a study appearing in the February 27 issue of JAMA. "Heart failure (HF) with preserved ejection fraction [EF; the percentage of blood that is pumped out of a filled ventricle as a result of a heartbeat is 50 percent or greater]...

COLUMBUS, Ohio, Feb. 27, 2013 /PRNewswire/ -- Metropolitan Methodist Hospital became the third hospital in the greater San Antonio region to achieve Colloquium Heart Failure Accreditation. Joining sister hospitals, Methodist Specialty & Transplant Hospital and Methodist Stone Oak Hospital, Metropolitan met twelve heart failure milestone requirements in four domains: Community, Hospital, Clinician, and Science. "We were a bit surprised to find that as a community hospital,...

-- Phase II, randomized, placebo-controlled, multi-center study will measure the primary efficacy endpoint of reduction in ventricular remodeling post-percutaneous coronary intervention (PCI) -- TORONTO, Feb. 27, 2013 /PRNewswire/ -- CellAegis Devices, Inc., announced today that it has received an Investigational Testing Approval (ITA) from Health Canada that allows the initiation of clinical testing in Canada of the Company's autoRIC(TM) Device for Chronic Remote Ischemic...

COLUMBUS, Ohio, Feb. 26, 2013 /PRNewswire/ -- The Healthcare Accreditation Colloquium announced today the first use of ST2, a new blood test for heart failure, as part of an accreditation process for hospitals. "Our work began in 2011," said Dr. Tony Joseph, Colloquium CEO. "We are proud of our member hospitals and heart failure experts that were able to see the value of this new blood test ahead of the crowd and be prepared to implement for the good of our patients once FDA clearance...

TUCSON, Ariz., Feb. 21, 2013 /PRNewswire/ -- At only 20 years old, Tiernee Gonzalez has been battling two major diseases for most of her young life: heart failure and kidney failure. When she became the first patient at Cincinnati Children's Hospital Medical Center to receive the SynCardia temporary Total Artificial Heart on Nov. 9, her doctors hoped it would bring her one step closer to winning her battle against end-stage heart failure. What they didn't expect, was that it...

SAN DIEGO, Feb. 20, 2013 /PRNewswire/ -- Ventrix, Inc. announced today that its VentriGel((TM)) cardiac repair scaffold safely and effectively mitigated left ventricular remodeling and improved cardiac function in pigs after myocardial infarction, or heart attack. The findings, made during pre-clinical studies, were published today in the journal Science Translational Medicine. Based on these and other results, Ventrix will initiate a first-in-man clinical trial for VentriGel later...

PALO ALTO, Calif., Feb. 19, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced the publication of the COMPASS (Coronary Obstruction Detection by Molecular Personalized Gene Expression) study in Circulation: Cardiovascular Genetics, a journal of the American Heart Association. Results of the prospective, multi-center U.S. study showed that Corus(®) CAD, a blood-based gene expression test, demonstrated high accuracy...